The Controlling Nutritional Status (CONUT) Score is a Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with First-Line Platinum-Based Chemotherapy

Overview

Journal Bladder Cancer

Publisher IOS Press

Date 2024 Jul 12

PMID 38993214

Authors

Hiroaki Suzuki

Masaya Ito

Kosuke Takemura

Shuichiro Kobayashi

Madoka Kataoka

Noriyuki Iida

Ken Sekiya

Takuya Matsumoto

Fumitaka Koga

Affiliations

Soon will be listed here.

Abstract

Background: The controlling nutritional status (CONUT) score is an objective indicator of general condition from the aspect of nutritional status, calculated from serum albumin, total cholesterol, and total lymphocyte count. The CONUT score is also considered to reflect the degree of tumor-derived chronic inflammation and the host immune status in patients with advanced cancer.

Objective: To examine the prognostic role of the CONUT score in patients with advanced urothelial carcinoma (aUC) treated with first-line platinum-based chemotherapy.

Methods: Associations of the CONUT score with clinical parameters and overall survival (OS) were investigated retrospectively in 147 patients with aUC receiving first-line platinum-based chemotherapy at a single cancer center from February 2003 to April 2019.

Results: The median (range) CONUT score was 1 (0-7). A higher CONUT score was associated with lower hemoglobin ( < 0.001) and higher C-reactive protein levels ( = 0.023) but not with chemotherapy response ( = 0.432). The median OS for patients with CONUT scores 0-1, 2-3, and ≥4 were 23.3, 14.9, and 9.4 months, respectively ( < 0.001). In the multivariable analysis, a higher CONUT score was independently associated with shorter OS (scores 2-3 vs 0-1, HR 1.58, = 0.048; scores ≥4 vs 0-1, HR 2.63, = 0.008) along with poorer performance status (HR 4.79, < 0.001), primary tumor site of the upper urinary tract (HR 1.70, = 0.016), higher LDH (HR 3.85, = 0.036), higher alkaline phosphatase (HR 3.06, = 0.028), and non-responders to chemotherapy (HR 2.07, < 0.001).

Conclusions: The CONUT score is a prognostic biomarker in patients with aUC receiving first-line platinum-based chemotherapy.

Citing Articles

Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA study.

Tanabe K, Kobayashi S, Maezawa Y, Ishihara K, Inoue N, Izumi K Int J Clin Oncol. 2024; 29(9):1302-1310.

PMID: 38833113 DOI: 10.1007/s10147-024-02563-7.

Controlling Nutritional Status (CONUT) Score and Sarcopenia as Mutually Independent Prognostic Biomarkers in Advanced Urothelial Carcinoma.

Une M, Ito M, Suzuki H, Toide M, Kobayashi S, Fukushima H Cancers (Basel). 2022; 14(20).

PMID: 36291858 PMC: 9600715. DOI: 10.3390/cancers14205075.

References

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Jiang Y, Li Y, Zhu B . T-cell exhaustion in the tumor microenvironment. Cell Death Dis. 2015; 6:e1792. PMC: 4669840. DOI: 10.1038/cddis.2015.162. View

Apolo A, Ostrovnaya I, Halabi S, Iasonos A, Philips G, Rosenberg J . Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. J Natl Cancer Inst. 2013; 105(7):499-503. PMC: 3691944. DOI: 10.1093/jnci/djt015. View

Wan S, Pestka S, Jubin R, Lyu Y, Tsai Y, Liu L . Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells. PLoS One. 2012; 7(3):e32542. PMC: 3291570. DOI: 10.1371/journal.pone.0032542. View

Toyokawa T, Kubo N, Tamura T, Sakurai K, Amano R, Tanaka H . The pretreatment Controlling Nutritional Status (CONUT) score is an independent prognostic factor in patients with resectable thoracic esophageal squamous cell carcinoma: results from a retrospective study. BMC Cancer. 2016; 16:722. PMC: 5013653. DOI: 10.1186/s12885-016-2696-0. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

Toyokawa G, Kozuma Y, Matsubara T, Haratake N, Takamori S, Akamine T . Prognostic impact of controlling nutritional status score in resected lung squamous cell carcinoma. J Thorac Dis. 2017; 9(9):2942-2951. PMC: 5708442. DOI: 10.21037/jtd.2017.07.108. View

Suzuki H, Ito M, Takemura K, Nakanishi Y, Kataoka M, Sakamoto K . Prognostic significance of the controlling nutritional status (CONUT) score in advanced urothelial carcinoma patients. Urol Oncol. 2019; 38(3):76.e11-76.e17. DOI: 10.1016/j.urolonc.2019.10.014. View

Johnson D, OKeefe R, Grandis J . Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018; 15(4):234-248. PMC: 5858971. DOI: 10.1038/nrclinonc.2018.8. View

10.

Saito K, Urakami S, Komai Y, Yasuda Y, Kubo Y, Kitsukawa S . Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin. BJU Int. 2012; 110(10):1478-84. DOI: 10.1111/j.1464-410X.2012.11153.x. View

11.

Lesterhuis W, Punt C, Hato S, Eleveld-Trancikova D, Jansen B, Nierkens S . Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest. 2011; 121(8):3100-8. PMC: 3148725. DOI: 10.1172/JCI43656. View

12.

de Ulibarri J, Gonzalez-Madrono A, de Villar N, Gonzalez P, Gonzalez B, Mancha A . CONUT: a tool for controlling nutritional status. First validation in a hospital population. Nutr Hosp. 2005; 20(1):38-45. View

13.

Bellmunt J, de Wit R, Vaughn D, Fradet Y, Lee J, Fong L . Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017; 376(11):1015-1026. PMC: 5635424. DOI: 10.1056/NEJMoa1613683. View

14.

Galsky M, Moshier E, Krege S, Lin C, Hahn N, Ecke T . Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. Cancer. 2013; 119(16):3012-9. DOI: 10.1002/cncr.28146. View

15.

Altman D, McShane L, Sauerbrei W, Taube S . Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med. 2012; 9(5):e1001216. PMC: 3362085. DOI: 10.1371/journal.pmed.1001216. View

16.

Bellmunt J, von der Maase H, Mead G, Skoneczna I, De Santis M, Daugaard G . Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012; 30(10):1107-13. PMC: 3341152. DOI: 10.1200/JCO.2011.38.6979. View

17.

de Biasi A, Villena-Vargas J, Adusumilli P . Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin Cancer Res. 2014; 20(21):5384-91. PMC: 4216745. DOI: 10.1158/1078-0432.CCR-14-1298. View

18.

Taylor M, Lee C, Makker V, Rasco D, Dutcus C, Wu J . Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. J Clin Oncol. 2020; 38(11):1154-1163. PMC: 7145588. DOI: 10.1200/JCO.19.01598. View

19.

Galsky M, Wang H, Hahn N, Twardowski P, Pal S, Albany C . Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. Eur Urol. 2017; 73(5):751-759. DOI: 10.1016/j.eururo.2017.12.001. View

20.

Hashizume M, Yoshida H, Koike N, Suzuki M, Mihara M . Overproduced interleukin 6 decreases blood lipid levels via upregulation of very-low-density lipoprotein receptor. Ann Rheum Dis. 2009; 69(4):741-6. DOI: 10.1136/ard.2008.104844. View